Product Information
Registration Status: ActiveSIN15892P
ENSTILAR® CUTANEOUS FOAM 50mcg/g + 0.5mg/g is approved to be sold in Singapore with effective from 2020-02-27. It is marketed by LEO PHARMA ASIA PTE LTD, with the registration number of SIN15892P.
This product contains Betamethasone Dipropionate 0.5mg/g, and Calcipotriol 52.2mcg/g in the form of AEROSOL, FOAM. It is approved for TOPICAL, CUTANEOUS use.
This product is manufactured by LEO Laboratories Ltd in IRELAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
Indication
For the treatment of moderate plaque psoriasis in adults.
Mechanism of Action
The precise mechanism of calcipotriol in remitting psoriasis is not well-understood. However, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor, while being less than 1% as active as the calcitriol in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis, and it is thought that the binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation related genes.
Pharmacokinetics
- Absorption
- Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.
- Distribution
- Metabolism
- Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound.
- Elimination
Toxicity
Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.
Active Ingredient/Synonyms
Calcipotriene | Calcipotriol | Daivonex | Calcipotriol |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.